Regulatory Delay on mRNA Flu Vaccine
regulatory response
investigated
The FDA has declined to review Moderna's submitted application for an mRNA-based influenza vaccine, effectively delaying potential approval and market entry.
This matters because it highlights the persistent regulatory friction slowing the transition from traditional to mRNA-based vaccines for endemic diseases, affecting both innovation trajectories and public health outcomes.